AIM ImmunoTech Inc [AIM] stock is trading at $0.21, down -4.80%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The AIM shares have gain 8.57% over the last week, with a monthly amount glided 12.68%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
AIM ImmunoTech Inc [AIM] stock has fluctuated between $0.16 and $0.62 over the past year. AIM ImmunoTech Inc [AMEX: AIM] shares were valued at $0.21 at the most recent close of the market.
Analyzing the AIM fundamentals
AIM ImmunoTech Inc [AMEX:AIM] reported sales of 0.19M for the trailing twelve months, which represents a drop of -23.91%. Gross Profit Margin for this corporation currently stands at 0.2% with Operating Profit Margin at -146.88%, Pretax Profit Margin comes in at -125.94%, and Net Profit Margin reading is -125.94%. To continue investigating profitability, this company’s Return on Assets is posted at -1.76, Equity is -3.98 and Total Capital is -8.0. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.17.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.2077 points at the first support level, and at 0.2013 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.2228, and for the 2nd resistance point, it is at 0.2315.
Ratios To Look Out For
For context, AIM ImmunoTech Inc’s Current Ratio is 0.75. Also, the Quick Ratio is 0.75, while the Cash Ratio stands at 0.09. Considering the valuation of this stock, the price to sales ratio is 76.26, the price to book ratio is 4.31.
Transactions by insiders
Recent insider trading involved Equels Thomas K, CEO & President, that happened on Nov 21 ’24 when 20000.0 shares were purchased. Director, MITCHELL WILLIAM M completed a deal on Dec 19 ’24 to sell 4580.0 shares. Meanwhile, CEO & President Equels Thomas K bought 22727.0 shares on Dec 18 ’24.
